Amgen Cholesterol Drug Repatha Turned Down By UK Cost Watchdog

Amgen's Repatha has been turned down for NHS funding by NICE. The UK cost watchdog said that analyses presented for the anti-cholesterol drug exhibited a high level of uncertainty, and thus cannot be recommended for use in Britain's state health.